Company Overview
Snapshot
Founded in May 2024, Ionara Bio operates with 1–10 employees. The company has secured $800,000 across two funding rounds from one investor. In November 2024, Peregrine Ventures led a Seed round, providing crucial early-stage capital.
Business overview
Ionara Bio is a Health Tech & Life Sciences company focused on developing novel small molecules. The company's core technology targets and blocks the TRPV2 channel, which is a key driver of inflammatory responses, particularly those involving macrophages that impair cardiac structure and function following acute myocardial infarction (AMI). Ionara Bio's lead candidate is a first-in-class TRPV2 inhibitor designed to improve cardiac function and reduce pathological cardiac fibrosis, aiming to enhance post-AMI recovery. The company operates within the Pharma & Medical Biotechnology sector, serving the Life Sciences and Healthcare industries, specifically targeting providers.
Log in to access full profile ›Company Intelligence Q&A
- What is Ionara Bio's primary focus?
- Ionara Bio is developing novel, proprietary small molecules designed to target and block the TRPV2 channel, which is implicated in inflammatory responses affecting cardiac function after acute myocardial infarction.
- When was Ionara Bio founded?
- Ionara Bio was founded in May 2024.
- How much capital has Ionara Bio raised to date?
- Ionara Bio has raised a total of $800,000 across two funding rounds.
- Which investor participated in Ionara Bio's funding rounds?
- Peregrine Ventures has invested in Ionara Bio, leading a Seed round in November 2024 and participating in another round in January 2026.
- What is the strategic goal of Ionara Bio's lead candidate?
- The company's lead candidate, a first-in-class TRPV2 inhibitor, is designed to improve cardiac function and reduce pathological cardiac fibrosis, aiming for significantly enhanced post-AMI recovery.